CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma...
Phase 2
Rochester, Minnesota, United States and 5 other locations
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irR...
Phase 2
Rochester, Minnesota, United States and 1 other location
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with pre...
Phase 2
Rochester, Minnesota, United States and 32 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Rochester, Minnesota, United States and 138 other locations
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN1...
Phase 1, Phase 2
Rochester, Minnesota, United States and 24 other locations
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph...
Phase 1, Phase 2
Rochester, Minnesota, United States and 27 other locations
The purpose of this study is to determine the response rate to the combination of folate receptor alpha dendritic cells (FRaDCs) plus pembrolizumab i...
Phase 1, Phase 2
Rochester, Minnesota, United States
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It...
Phase 1, Phase 2
Rochester, Minnesota, United States and 21 other locations
The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...
Phase 3
Rochester, Minnesota, United States and 199 other locations
This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced,...
Phase 1, Phase 2
Rochester, Minnesota, United States and 20 other locations
Clinical trials
Research sites
Resources
Legal